Ajanta Pharma Buyback 2020
(i) Ajanta Pharma is a specialty pharmaceutical company engaged in the development, manufacturing, and marketing of quality finished dosages. Committed to ‘Serve Health Care Needs Worldwide’, they produce a comprehensive range of specialty products targeting different therapeutic segments for the treatment of patients, customized to each market.
(ii) Their business includes Branded Generics in emerging markets of Asia and Africa, Generics in the developed markets of USA and Institution sales.
(iii) The branded generics business is spread in India and more than 30 emerging countries across Africa, CIS, the Middle East and South East Asia. In India, they have a presence in high growth specialty segments of cardiology, dermatology, ophthalmology and pain management where they have been able to provide consistently innovative products, many being 1st to the market, for patient convenience and compliance.
Buy Back Offer Deal:
Buyback Type: | Tender Offer |
Buyback Record Date: | Nov 13 2020 |
Buyback Opening Date: | Dec 03 2020 |
Buyback Closing Date: | Dec 16 2020 |
Buyback Offer Amount: | ₹ 135 |
Date of Board Meeting approving the proposal: | Nov 03 2020 |
Date of Public Announcement: | Nov 03 2020 |
Buyback Offer Size: | 0.84% |
Buyback Number of Shares: | 7,35,000 |
Price Type: | Tender Offer |
FV: | 2 |
Buyback Price: | ₹ 1850 Per Equity Share |
Details of Buyback:
Salient financial parameters:
Particulars (Cr) | Mar-15 | Mar-16 | Mar-17 | Mar-18 | Mar-19 | Mar-20 |
Sales | 1,474 | 1,749 | 1,983 | 2,126 | 2,055 | 2,588 |
Expenses | 969 | 1,161 | 1,292 | 1,467 | 1,489 | 1,904 |
Operating Profit | 504 | 589 | 691 | 658 | 567 | 683 |
OPM % | 34% | 34% | 35% | 31% | 28% | 26% |
Other Income | 9 | 20 | 20 | 24 | 21 | 88 |
Interest | 6 | 5 | 1 | 0 | 1 | 12 |
Depreciation | 52 | 44 | 61 | 60 | 72 | 96 |
Profit before tax | 456 | 559 | 648 | 623 | 514 | 664 |
Tax % | 32% | 26% | 22% | 25% | 25% | 30% |
Net Profit | 310 | 416 | 507 | 469 | 387 | 468 |
EPS in Rs | 35.25 | 47.23 | 57.59 | 53.25 | 44.35 | 53.6 |
Dividend Payout % | 17% | 17% | 23% | 0% | 20% | 24% |
How to Participate in buyback?
Profit from the buyback on the bases of acceptance Ratio:
Acceptance Ratio | 33% | 50% | 75% | 100% |
Amount Invested in Buyback | 199800 | 199800 | 199800 | 199800 |
No. of Shares buyback | 36 | 54 | 81 | 108 |
BuyBack Profit | 8197 | 12420 | 18630 | 24840 |
Profit | 4.10% | 6.22% | 9.32% | 12.43% |
Recommendation:
26 Comments
Leave a Reply
You must be logged in to post a comment.
If my all 20 ajanta pahrma shares are accepted for buyback, when i will get money in to my account.
Still the shares are appearing in the portfolio.
hi,
How do i come to know that my 20 Ajanta pharma shares tendered for buyback are accepted or not. From my demat allocation it is not appearing.
hi,
How do i come to know that my 20 shares tendered are accepted or not. From my demat allocation it is not appearing.
Hi ,
Can anyone tell me when we get the buyback amount or unacceptable share in demand.
Today on 24/12 I have checked my demat, I have not received any amount of the buyback
I had 40 left
Entitlement was 11
20 accepted
According to 35%
21 should have been accepted
118*9.08=10.7144 (Entitled)
29*0.35=10.15 (Additional)
Total => 20.8644
Rounded off in lower side =>20
For more accurate calculation:-
118(on RD)*9.08% (ER)=10.7144 (Ent)
40 (Tendered)-10.7144(Ent)= 29.2856 (Additional Tendered)
29.2856 (AT)*0.35 (AR)=10.24996 (Additional Accepted)
Total => 10.7144 (Ent)+10.24996 (AA)
=> 20.96436
Rounded Off in lower side => 20 (Accepted)
(As per my view, if I am not wrong)
42 out of 120 accepted in retail…not a bad one compared to the 11 entitlement…
4 out of 10 Accepted.
36% acceptance …great !! also the CMP is at a good zone.. for those looking to exit out of the unaccepted shares.
Ajanta pharma 1 share accepted in Buyback.
How did you know? how to check?
Ajantapharma me sirf NSE me hi buyback hai ?
11 out of 118
Entitlement
What is likely acceptance ratio
I had 118 shares on record date
Now I have 40
Should I buy more
And tender them
Reply anyone
Buyback has started
https://linkintime.co.in/website/GoGreen/2020/Update/Ajanta_Pharma_Limited/Ajanta_Letter_of_Offer.pdf
Retail Entitlement Ratio is 11 Equity Shares out of every 116 fully paid-up Equity Shares held on the Record Date = 9.48%
Final Analysis of Ajanta Pharma Technologies 2019 ( Return Analysis)
1. Buyback Announcement date: 30.01.2019—– Share Price was 1089
2. 153 Shares bought at Rs. 1089 means an investment of 1,67,538.
3. Retail Acceptance Ratio was 20%. i.e. out of 153 shares, 30 shares have been buyback by the company. Profit on Accepted Shares= 6330
4. The 123 Unaccepted shares were given back on 22.03.2019. The price on 22.03.2019 is 1007, so if you sell 123 shares in 1007, then it is a loss of 10086.
5. Overall we can say a loss of 3756 on Ajanta Pharma Buyback.
OR
1. Draft letter issued: 06.02.2019—– Share Price was 925
2. 153 Shares bought at Rs. 925 means an investment of 1,41,525.
3. Retail Acceptance Ratio was 20%. i.e. out of 153 shares, 30 shares have been buyback by the company. Profit on Accepted Shares= 11250
4. The 123 Unaccepted shares were given back on 22.03.2019. The price of 22.03.2019 is 1007, so if you sell 123 shares in 1007, then it is a profit of 10600.
5. Overall we can say a profit of 21850 on Ajanta Pharma Buyback.
See the above two strategies, had you bought after the announcement of Record date you still would have made a very good profit from Ajanta Buyback. So it is the game of strategy.
Why not a page for Cosmo film also
Buy back price 576
Record date 13 Nov
Hpcl also announced buyback
14% arbitrage is there between CMP and Buyback Price. However, the size of buyback is very small.
Is there any chances if share cracking after record date
Is it a safe bet like wilro/tcs
i think last year buyback was1300 when it is near to 909 this time want wait for buyback price
opened
Please open new page for ntpc, meeting for buy back on 02.11.2020